Auro Laboratories Ltd Hits New 52-Week High of Rs.308.9 on 12 Feb 2026

Stock Performance and Price Movement

On the day of this milestone, Auro Laboratories Ltd’s stock touched an intraday high of Rs.308.9, representing a 3.12% increase from the previous close. Despite this peak, the stock closed with a slight decline of 1.19% for the day, underperforming its sector by 1.06%. The intraday low was recorded at Rs.282.2, down 5.79% from the prior close, indicating some volatility during trading hours.

The stock’s current price level is well above its 52-week low of Rs.159, highlighting a robust upward trajectory over the past year. This translates to a 34.55% gain in the last 12 months, significantly outperforming the Sensex’s 10.14% rise over the same period.

Technical Indicators and Moving Averages

Auro Laboratories Ltd is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning underscores the stock’s strong upward momentum and suggests sustained investor confidence in its price trend.

However, it is noteworthy that after eight consecutive days of gains, the stock experienced a reversal on 12 Feb 2026, closing lower despite reaching the new high intraday. This pullback may reflect short-term profit-taking or market fluctuations.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector, in which Auro Laboratories Ltd operates, has shown mixed performance on the day. While the stock reached a new high, the broader market indices reflected some caution. The Sensex opened 265.21 points lower and was trading at 83,878.35, down 0.42%. Despite this, the Sensex remains close to its own 52-week high, just 2.72% shy of 86,159.02.

Over the past three weeks, the Sensex has gained 2.87%, supported by a 50-day moving average that remains above the 200-day average, signalling a generally positive medium-term trend. However, the index is currently trading below its 50-day moving average, indicating some near-term pressure.

Mojo Score and Rating Update

Auro Laboratories Ltd holds a Mojo Score of 62.0, categorised as a Hold rating. This represents an upgrade from a previous Sell rating as of 6 Feb 2026. The company’s Market Cap Grade stands at 4, reflecting its mid-tier market capitalisation within the Pharmaceuticals & Biotechnology sector.

The upgrade in rating aligns with the stock’s recent price strength and improved technical indicators, though the Hold status suggests a cautious stance on further near-term gains.

Year-Long Performance and Relative Strength

Over the past year, Auro Laboratories Ltd has demonstrated considerable strength relative to the broader market. Its 34.55% gain outpaces the Sensex’s 10.14% rise by a wide margin, underscoring the stock’s resilience and appeal within its sector.

This outperformance is further supported by the stock’s ability to maintain levels above all major moving averages, signalling sustained buying interest and positive price momentum.

Price Volatility and Intraday Dynamics

The stock’s intraday range on 12 Feb 2026 was notably wide, with a low of Rs.282.2 and a high of Rs.308.9. This 9.3% range reflects active trading and some volatility, which is not uncommon when a stock approaches or surpasses significant technical milestones such as a 52-week high.

Despite the intraday high, the stock’s close below that peak suggests some profit-taking or cautious positioning by market participants at these elevated levels.

Summary of Key Metrics

To summarise, Auro Laboratories Ltd’s key metrics as of 12 Feb 2026 are:

• New 52-week high: Rs.308.9
• Intraday low: Rs.282.2
• Day’s closing change: -1.19%
• Mojo Score: 62.0 (Hold rating)
• Market Cap Grade: 4
• 1-year price gain: 34.55%
• Sensex 1-year gain: 10.14%

These figures illustrate the stock’s strong performance and recent technical achievements within a competitive sector environment.

Conclusion

Auro Laboratories Ltd’s attainment of a new 52-week high at Rs.308.9 marks a significant milestone in its price journey. The stock’s sustained gains over the past year, supported by positive technical indicators and an upgraded rating, highlight its momentum within the Pharmaceuticals & Biotechnology sector. While the day’s trading showed some volatility and a minor pullback, the overall trend remains robust compared to broader market benchmarks.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →